CAS 497223-25-3 appears in our catalog under these names: Cenicriviroc, Cenicriviroc/ 98.98% (existing batch purity), Cenicriviroc 95%, 8-[4-(2-Butoxyethoxy)phenyl]-1,2,3,4-tetrahydro-1-(2-methylpropyl)-N-[4-[(S)-[(1-propyl-1H-imidazol-5-yl)methyl]sulfinyl]phenyl]-1-benzazocine-5-carboxamide, 95%, 95%, Cenicriviroc, 99.51%. Offered by: GLPBio, Chemat Brand, TRC, TargetMol, Ambeed. Available pack sizes: 25mg, on request, 1mg, 2mg, 5mg, 10mg, 50mg, 100mg.
Cenicriviroc is a member of the class of benzazocines that is (5Z)-1,2,3,4-tetrahydro-1-benzazocine which is substituted by a 2-methylpropyl, N-{4-[(S)-(1-propyl-1H-imidazol-5-yl)methanesulfinyl]phenyl}carboxamide and 4-(2-butoxyethoxy)phenyl groups at positions 1, 5 and 8, respectively. It is a potent chemokine 2 and 5 receptor antagonist currently in development for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis (NASH). It has a role as a chemokine receptor 2 antagonist, an antifibrotic agent, an antirheumatic drug, a chemokine receptor 5 antagonist, an anti-HIV agent and an anti-inflammatory agent. It is a secondary carboxamide, a sulfoxide, a member of imidazoles, an aromatic ether, a benzazocine and a diether.
Source: ChEBI
| Molecular formula | C41H52N4O4S |
|---|---|
| Molecular weight | 696.9 g/mol |
| IUPAC name | (5E)-8-[4-(2-butoxyethoxy)phenyl]-1-(2-methylpropyl)-N-[4-[(S)-(3-propylimidazol-4-yl)methylsulfinyl]phenyl]-3,4-dihydro-2H-1-benzazocine-5-carboxamide |
| InChIKey | PNDKCRDVVKJPKG-WHERJAGFSA-N |
| SMILES | CCCCOCCOC1=CC=C(C=C1)C2=CC/3=C(C=C2)N(CCC/C(=C3)/C(=O)NC4=CC=C(C=C4)[S@@](=O)CC5=CN=CN5CCC)CC(C)C |
Computed by PubChem (NCBI)